[Retracted] The Application of Molecular Techniques for Assessment of SOX2 and miR126 Expression as Prognostic Markers in Esophageal Carcinoma

Table 1

SOX2 and miR-126 expression and clinical and pathological data.

		miR-126		P	SOX2		P
		Mean	SD		Mean	SD
Sex
Male	30	0.95	0.57	0.81	4.39	0.55	0.91
Female	5	1.02	0.78		4.36	0.57
Location
Cervical	5	1.71	0.09	<0.00	5.21	0.22	<0.0001
Thoracic	17	1.22	0.37	01	4.59	0.20
Abdominal	13	0.33	0.23		3.80	0.20
Pathology
Adeno^a	20	1.17	0.58	0.010	4.60	0.57	0.0045
SCC^b	15	0.67	0.48	1	4.10	0.34
Albumin, g/dl
≤3.7	15	1.56	0.15	<0.00	4.88	0.28	<0.0001
>3.7	20	0.51	0.33	01	4.02	0.36
Grade
I	12	1.62	0.11	<0.00	4.94	0.28	<0.0001
II	10	0.98	0.30	01	4.48	0.17
III	8	0.47	0.17		3.93	0.03
IV	5	0.10	0.07		3.59	0.16
T
T1	12	1.62	0.11	<0.00	4.94	0.28	<0.0001
T2	7	1.11	0.26	01	4.58	0.07
T3	10	0.56	0.15		4.04	0.17
T4	6	0.13	0.08		3.63	0.19
N
N0	13	1.6	0.12	<0.00	4.9	0.3	<0.0001
N1	16	0.75	0.31	01	4.2	0.3
N2	6	0.13	0.08		3.6	0.2
Stage
I	14	1.58	0.13	<0.00	4.90	0.28	<0.0001
II	15	0.57	0.22	01	4.11	0.26
III	6	0.47	0.60		3.89	0.57

^aAdenocarcinoma, ^bsquamous cell carcinoma, and Student’s t-test. Analysis of variance (ANOVA).